恶性胸膜间皮瘤中的循环表观遗传生物标志物：现状与批判性评价
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
作者信息
Ferrari Luca, Carugno Michele, Mensi Carolina, Pesatori Angela Cecilia
机构信息
EPIGET LAB, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
Epidemiology Unit, Department of Preventive Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
出版信息
Front Oncol. 2020 Apr 3;10:445. doi: 10.3389/fonc.2020.00445. eCollection 2020.
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which originates from the mesothelial cells of the pleura and is associated with asbestos exposure. In light of its aggressive nature, late diagnosis and dismal prognosis, there is an urgent need for identification of biomarkers in easily accessible samples (such as blood) for early diagnosis of MPM. In the last 10 years, epigenetic markers, such as DNA methylation and microRNAs (miRNAs), have gained popularity as possible early diagnostic and prognostic biomarkers in cancer research. The aim of this review is to provide a critical analysis of the current evidences on circulating epigenetic biomarkers for MPM and on their translational potential to the clinical practice for early diagnosis and for prognosis.
摘要
恶性胸膜间皮瘤（MPM）是一种罕见且侵袭性强的癌症，起源于胸膜间皮细胞，与石棉暴露有关。鉴于其侵袭性、诊断延迟和预后不良的特点，迫切需要在易于获取的样本（如血液）中鉴定生物标志物，以实现MPM的早期诊断。在过去十年中，表观遗传标志物，如DNA甲基化和微小RNA（miRNA），在癌症研究中作为可能的早期诊断和预后生物标志物受到了广泛关注。本综述的目的是对MPM循环表观遗传生物标志物的现有证据及其在早期诊断和预后临床实践中的转化潜力进行批判性分析。
相似文献
1
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.恶性胸膜间皮瘤中的循环表观遗传生物标志物：现状与批判性评价
Front Oncol. 2020 Apr 3;10:445. doi: 10.3389/fonc.2020.00445. eCollection 2020.
2
The Use of Immunohistochemistry, Fluorescence Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review.免疫组织化学、荧光杂交及新兴表观遗传标志物在恶性胸膜间皮瘤（MPM）诊断中的应用：综述
Front Oncol. 2020 Sep 9;10:1742. doi: 10.3389/fonc.2020.01742. eCollection 2020.
3
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.恶性胸膜间皮瘤中的液体活检：现状、陷阱与展望
Front Oncol. 2019 Aug 14;9:740. doi: 10.3389/fonc.2019.00740. eCollection 2019.
4
Circulating biomarkers in malignant pleural mesothelioma.恶性胸膜间皮瘤中的循环生物标志物
Explor Target Antitumor Ther. 2020;1(6):434-451. doi: 10.37349/etat.2020.00028. Epub 2020 Dec 28.
5
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.区分恶性与良性间皮性胸膜增生的分子标志物和新诊断方法：文献综述
J Thorac Dis. 2018 Jan;10(Suppl 2):S342-S352. doi: 10.21037/jtd.2017.10.88.
6
Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.恶性胸膜间皮瘤和石棉暴露受试者血浆细胞外囊泡微小RNA提示一种双微小RNA特征可作为疾病的潜在生物标志物。
PLoS One. 2017 May 4;12(5):e0176680. doi: 10.1371/journal.pone.0176680. eCollection 2017.
7
MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.微小 RNA-98 是石棉诱导性间皮瘤的一个预后因素。
J Toxicol Environ Health A. 2020 Feb 1;83(3):126-134. doi: 10.1080/15287394.2020.1734891. Epub 2020 Mar 2.
8
MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.用于恶性胸膜间皮瘤诊断与管理的微小RNA：文献综述
Front Oncol. 2018 Dec 21;8:650. doi: 10.3389/fonc.2018.00650. eCollection 2018.
9
MicroRNAs dysregulation in human malignant pleural mesothelioma.人类恶性胸膜间皮瘤中 microRNAs 的失调。
J Thorac Oncol. 2011 May;6(5):844-51. doi: 10.1097/JTO.0b013e31820db125.
10
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.骨桥蛋白和血清间皮素在恶性胸膜间皮瘤诊断及预后评估中的应用价值。
Clin Cancer Res. 2007 May 15;13(10):2928-35. doi: 10.1158/1078-0432.CCR-06-2144.
引用本文的文献
1
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets.恶性胸膜间皮瘤：从病理生理学到创新的可操作靶点
Cancers (Basel). 2025 Mar 30;17(7):1160. doi: 10.3390/cancers17071160.
2
miRNAs in the diagnosis and therapy of cardiac and mediastinal tumors: a new dawn for cardio-oncology?微小RNA在心脏和纵隔肿瘤诊断与治疗中的应用：心脏肿瘤学的新曙光？
Future Cardiol. 2024;20(14):795-806. doi: 10.1080/14796678.2024.2419225. Epub 2024 Nov 8.
3
Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos.对恶性胸膜间皮瘤患者血清中循环 microRNA 197-3p 的表观遗传学研究及曾接触石棉的工人。
Sci Rep. 2023 Apr 20;13(1):6501. doi: 10.1038/s41598-023-33116-z.
4
Next Generation Sequencing for miRNA Detection on the Exhaled Breath Condensate: A Pilot Study.用于检测呼出气冷凝物中微小RNA的下一代测序：一项初步研究。
Epigenet Insights. 2023 Apr 2;16:25168657231160985. doi: 10.1177/25168657231160985. eCollection 2023.
5
Serum diagnostic markers for malignant pleural mesothelioma: a narrative review.恶性胸膜间皮瘤的血清诊断标志物：一篇叙述性综述。
Transl Cancer Res. 2022 Dec;11(12):4434-4440. doi: 10.21037/tcr-22-2873.
6
Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study.在一项欧洲前瞻性研究中，血清细胞外囊泡衍生的微小RNA作为胸膜间皮瘤的潜在生物标志物
Cancers (Basel). 2022 Dec 25;15(1):125. doi: 10.3390/cancers15010125.
7
Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma.鉴定用于恶性胸膜间皮瘤诊断的新型潜在浆液体标志物组合。
Med Lav. 2022 Dec 7;113(6):e2022052. doi: 10.23749/mdl.v113i6.13522.
8
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms.间皮瘤恶性肿瘤与微环境：分子机制
Cancers (Basel). 2021 Nov 12;13(22):5664. doi: 10.3390/cancers13225664.
9
Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.正中靶心：间皮素作为恶性胸膜间皮瘤生物标志物和治疗靶点的作用
Cancers (Basel). 2021 Aug 4;13(16):3932. doi: 10.3390/cancers13163932.
10
Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.间皮瘤中的肿瘤免疫微环境与基因改变
Front Oncol. 2021 Jun 23;11:660039. doi: 10.3389/fonc.2021.660039. eCollection 2021.
本文引用的文献
1
Genetic predisposition for malignant mesothelioma: A concise review.恶性间皮瘤的遗传易感性：简要综述。
Mutat Res Rev Mutat Res. 2019 Jul-Sep;781:1-10. doi: 10.1016/j.mrrev.2019.03.001. Epub 2019 Mar 6.
2
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.用于预测接受新辅助化疗和手术治疗的恶性胸膜间皮瘤患者预后的液体活检中的miR-625-3p和lncRNA GAS5
Noncoding RNA. 2019 Jun 17;5(2):41. doi: 10.3390/ncrna5020041.
3
Extracellular vesicles in the tumor microenvironment: old stories, but new tales.肿瘤微环境中的细胞外囊泡：旧故事，但新传说。
Mol Cancer. 2019 Mar 30;18(1):59. doi: 10.1186/s12943-019-0980-8.
4
Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response.循环血液中的微小RNA作为癌症诊断和手术治疗反应的生物标志物
Front Genet. 2019 Mar 11;10:169. doi: 10.3389/fgene.2019.00169. eCollection 2019.
5
Tumour biomarkers-Tracing the molecular function and clinical implication.肿瘤标志物——追踪分子功能和临床意义。
Cell Prolif. 2019 May;52(3):e12589. doi: 10.1111/cpr.12589. Epub 2019 Mar 14.
6
Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.循环微RNA是否适用于恶性间皮瘤的早期检测？一项巢式病例对照研究的结果。
BMC Res Notes. 2019 Feb 11;12(1):77. doi: 10.1186/s13104-019-4113-7.
7
[Malignant mesothelioma and constitutional BAP1 gene mutations].[恶性间皮瘤与体质性BAP1基因突变]
Rev Mal Respir. 2019 Feb;36(2):241-248. doi: 10.1016/j.rmr.2017.11.014. Epub 2019 Jan 24.
8
Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy.无细胞游离 DNA 中的表观遗传生物标志物及其在液体活检中的应用。
Genes (Basel). 2019 Jan 9;10(1):32. doi: 10.3390/genes10010032.
9
Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection.循环 microRNAs 与 PSA 联合用于准确、无创的前列腺癌检测。
Carcinogenesis. 2019 Apr 29;40(2):246-253. doi: 10.1093/carcin/bgy167.
10
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.外周血 DNA 甲基化作为石棉暴露人群恶性胸膜间皮瘤的潜在生物标志物。
J Thorac Oncol. 2019 Mar;14(3):527-539. doi: 10.1016/j.jtho.2018.10.163. Epub 2018 Nov 5.
Zotero 插件